Narrative review examines metabolic syndrome and novel agents in kidney transplant recipients

Photo by National Cancer Institute / Unsplash

Frontiers in Medicine Published May 21, 2026 Medically reviewed May 21, 2026 DOI ↗ By Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease

Key Takeaway

Consider integrated immunometabolic strategies for optimizing graft and patient survival in kidney transplantation.

This narrative review focuses on kidney transplantation recipients and covers conditions including antibody-mediated rejection, metabolic syndrome, post-transplant diabetes mellitus, dyslipidemia, and hypertension. It also discusses medications such as complement inhibitors, anti-CD38 antibodies, SGLT2 inhibitors, and GLP-1 receptor agonists. The scope includes graft failure, metabolic profiles, and long-term efficacy as secondary outcomes.

The authors report that 30% to 50% of kidney transplantation recipients develop metabolic syndromes within the first year. Antibody-mediated rejection remains a leading cause of late graft failure. The review highlights a bidirectional relationship between immune injury and metabolic dysregulation.

The authors acknowledge that data on long-term efficacy of novel agents remain limited. Safety data, adverse events, and tolerability were not reported in this review. The review does not provide specific sample sizes or follow-up durations. Practice relevance centers on the need for integrated immunometabolic strategies to optimize graft and patient survival.

Study Details

Study typeSystematic review

EvidenceLevel 1

PublishedMay 2026

View Original Abstract ↓

BackgroundKidney transplantation (KT) improves survival in end-stage renal disease, but long-term outcomes are undermined by antibody-mediated rejection (ABMR) and metabolic complications. Recent insights suggest a mechanistic interplay between immune injury and metabolic dysregulation.MethodsThis narrative review synthesizes current literature on the pathogenesis and clinical impact of antibody-mediated rejection (ABMR), the epidemiology of post-transplant metabolic syndrome—including post-transplant diabetes mellitus, dyslipidemia, and hypertension—and their bidirectional relationship. Emerging diagnostic tools and therapeutic strategies are also examined.ResultsABMR remains a leading cause of late graft failure. Concurrently, 30% ~ 50% of KT recipients develop metabolic syndromes within the first year, driven by immunosuppressive agents and underlying risk factors. Metabolic abnormalities enhance endothelial activation and complement-driven inflammation, aggravating ABMR. Conversely, immunosuppressive intensification to treat ABMR worsens metabolic profiles, forming a vicious cycle. Novel immunologic (e.g., complement inhibitors, anti-CD38 antibodies) and metabolic (e.g., SGLT2 inhibitors, GLP-1 receptor agonists) agents show promise, though data on long-term efficacy remain limited.ConclusionIntegrated immunometabolic strategies are essential for optimizing graft and patient survival. Future research should focus on personalizing immunosuppression and targeting metabolic health to break the feedback loop linking ABMR and metabolic disease.